Teva Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Teva Pharma Industries
TEVA Stock  USD 16.48  0.23  1.38%   
Teva Pharma financial statements provide useful quarterly and yearly information to potential Teva Pharma Industries investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Teva Pharma financial statements helps investors assess Teva Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Teva Pharma's valuation are summarized below:
Gross Profit
8.1 B
Profit Margin
(0.1)
Market Capitalization
19.1 B
Enterprise Value Revenue
2.0344
Revenue
16.5 B
We have found one hundred twenty available fundamental trend indicators for Teva Pharma Industries, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Teva Pharma Industries current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Enterprise Value is expected to grow to about 34.2 B, whereas Market Cap is forecasted to decline to about 13.9 B.

Teva Pharma Total Revenue

9.74 Billion

Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 1.1 B or Total Revenue of 9.7 B, as well as many indicators such as Price To Sales Ratio of 1.45, Dividend Yield of 0.0041 or PTB Ratio of 4.47. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
  
Check out the analysis of Teva Pharma Correlation against competitors.

Teva Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets26.8 B39.3 B48.9 B
Very volatile
Short and Long Term Debt Total9.6 B18.1 B19.1 B
Slightly volatile
Other Current Liabilities9.3 B8.8 B4.8 B
Slightly volatile
Total Current Liabilities6.7 B12.8 B12.2 B
Very volatile
Total Stockholder Equity9.8 B5.4 B15.7 B
Slightly volatile
Property Plant And Equipment Net3.3 B4.9 B6 B
Very volatile
Net Debt8.3 B14.8 B16.9 B
Slightly volatile
Cash3.5 B3.3 B2.3 B
Slightly volatile
Non Current Assets Total19 B26.8 B35.9 B
Very volatile
Non Currrent Assets Other592.2 M462 M793.2 M
Slightly volatile
Cash And Short Term Investments3.5 B3.3 B2.3 B
Slightly volatile
Net Receivables3 B3.1 B4.8 B
Pretty Stable
Common Stock Shares Outstanding789 M1.1 B950.9 M
Slightly volatile
Liabilities And Stockholders Equity26.8 B39.3 B48.9 B
Very volatile
Non Current Liabilities Total21.9 B20.8 B21.1 B
Slightly volatile
Inventory2.4 B3 B4 B
Pretty Stable
Other Current Assets3.3 B3.2 B1.5 B
Slightly volatile
Other Stockholder Equity24.9 B23.7 B17.7 B
Slightly volatile
Total Liabilities35.3 B33.6 B33.8 B
Slightly volatile
Total Current Assets7.9 B12.6 B13 B
Very volatile
Short Term Debt1.3 B1.8 B2.2 B
Pretty Stable
Intangible Assets4.7 B4.4 B8.7 B
Very volatile
Accounts Payable2.1 B2.2 B3.3 B
Slightly volatile
Short Term Investments1.2 B1.1 B511.7 M
Slightly volatile
Common Stock56 M51.3 M58 M
Slightly volatile
Other Liabilities5.3 B5.1 B3.3 B
Slightly volatile
Long Term Debt12.7 B16 B17.1 B
Slightly volatile
Property Plant Equipment4.8 B7.1 B6.1 B
Pretty Stable
Current Deferred Revenue3.1 B5.7 B4.2 B
Slightly volatile
Good Will17.6 B15.1 B20.3 B
Pretty Stable
Common Stock Total Equity53.7 M65.5 M53.3 M
Slightly volatile
Property Plant And Equipment Gross5.9 B9.4 B6.8 B
Slightly volatile
Long Term Investments52.2 M54.9 M198.7 M
Slightly volatile
Short and Long Term Debt2.5 B1.8 B4.8 B
Slightly volatile
Deferred Long Term Liabilities824.2 M867.6 M1.5 B
Pretty Stable
Long Term Debt Total26.3 B26.1 B19.1 B
Slightly volatile
Capital Surpluse27.4 B31.7 B23.6 B
Slightly volatile
Preferred Stock Total Equity3.9 B4.2 B3.6 B
Slightly volatile
Noncontrolling Interest In Consolidated Entity890.4 M869.4 M1.2 B
Slightly volatile
Additional Paid In Capital18.8 B21.1 B23 B
Slightly volatile
Net Invested Capital28 B23.2 B39.4 B
Slightly volatile
Capital Stock62.5 M58 M56.8 M
Slightly volatile
Deferred Long Term Asset Charges414.7 M443.9 M381.3 M
Slightly volatile
Capital Lease Obligations306 M296 M407.2 M
Slightly volatile

Teva Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 B1.3 B956.6 M
Pretty Stable
Interest Expense1.1 B1 B768.9 M
Slightly volatile
Total Revenue9.7 B16.5 B16.8 B
Very volatile
Gross Profit4.9 B8.1 B8.4 B
Pretty Stable
Other Operating Expenses17.7 B16.8 B14.3 B
Slightly volatile
Cost Of Revenue4.8 B8.5 B8.4 B
Very volatile
Total Operating Expenses8.8 B8.4 B5.7 B
Slightly volatile
Research Development818.5 M998 M1.2 B
Pretty Stable
Selling General Administrative1.2 B1.2 B1.1 B
Slightly volatile
Selling And Marketing Expenses3.2 B2.5 B3 B
Pretty Stable
Non Recurring5.6 B5.3 B3.9 B
Slightly volatile
Interest Income714.6 M948.8 M584.1 M
Slightly volatile
Preferred Stock And Other Adjustments203.6 M224.1 M250.1 M
Slightly volatile
Reconciled Depreciation1.2 B1.1 B1.8 B
Slightly volatile

Teva Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation133.3 M123 M101.9 M
Slightly volatile
Begin Period Cash Flow3.4 B3.2 B2.2 B
Slightly volatile
Depreciation779.1 M1.1 B1.3 B
Very volatile
Other Non Cash Items1.6 B3.1 B3 B
Pretty Stable
Dividends Paid56.8 M59.8 M511.1 M
Slightly volatile
Capital Expenditures488.2 M498 M666 M
Slightly volatile
Total Cash From Operating Activities1.9 B1.2 B2.7 B
Slightly volatile
End Period Cash Flow3.5 B3.3 B2.3 B
Slightly volatile
Change To Netincome1.2 B1.2 B2.9 B
Very volatile
Exchange Rate Changes43.2 M48.6 M53 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.451.52846.5069
Slightly volatile
Dividend Yield0.00410.00430.0165
Slightly volatile
PTB Ratio4.474.706211.2567
Slightly volatile
Days Sales Outstanding13167.4888107
Slightly volatile
Book Value Per Share8.385.048517.1055
Slightly volatile
Operating Cash Flow Per Share1.641.10062.8289
Slightly volatile
Stock Based Compensation To Revenue0.00460.00740.0058
Slightly volatile
Capex To Depreciation0.450.47030.5822
Slightly volatile
PB Ratio4.474.706211.2567
Slightly volatile
EV To Sales2.32.42187.4701
Slightly volatile
Inventory Turnover2.282.82042.1193
Slightly volatile
Days Of Inventory On Hand143129173
Slightly volatile
Payables Turnover2.813.84984.0175
Slightly volatile
Sales General And Administrative To Revenue0.05110.07020.0641
Slightly volatile
Research And Ddevelopement To Revenue0.05170.06030.0667
Slightly volatile
Capex To Revenue0.02860.03010.0398
Slightly volatile
Cash Per Share3.062.91262.3918
Pretty Stable
POCF Ratio26.020.27854.3293
Slightly volatile
Capex To Operating Cash Flow0.420.39940.4514
Pretty Stable
Days Payables Outstanding13794.811397.9027
Slightly volatile
EV To Operating Cash Flow31.2632.129665.8889
Slightly volatile
Intangibles To Total Assets0.280.49750.5223
Pretty Stable
Current Ratio1.670.98091.1618
Pretty Stable
Receivables Turnover5.685.40833.7211
Slightly volatile
Shareholders Equity Per Share8.184.742316.5206
Slightly volatile
Debt To Equity3.533.36481.7193
Slightly volatile
Capex Per Share0.420.43950.6955
Slightly volatile
Revenue Per Share7.9814.601917.0936
Slightly volatile
Interest Debt Per Share17.6816.841119.9853
Slightly volatile
Debt To Assets0.260.45970.3758
Slightly volatile
Graham Number11.078.0218.1983
Slightly volatile
Short Term Coverage Ratios0.950.70021.18
Slightly volatile
Operating Cycle328197283
Slightly volatile
Price Book Value Ratio4.474.706211.2567
Slightly volatile
Days Of Payables Outstanding13794.811397.9027
Slightly volatile
Price To Operating Cash Flows Ratio26.020.27854.3293
Slightly volatile
Company Equity Multiplier7.697.31924.0216
Slightly volatile
Long Term Debt To Capitalization0.790.74860.5325
Slightly volatile
Total Debt To Capitalization0.810.77090.5685
Slightly volatile
Debt Equity Ratio3.533.36481.7193
Slightly volatile
Quick Ratio1.110.74590.7975
Pretty Stable
Dividend Paid And Capex Coverage Ratio1.612.5042.2211
Slightly volatile
Net Income Per E B T1.341.27650.866
Slightly volatile
Cash Ratio0.280.25790.2126
Very volatile
Cash Conversion Cycle96.99102203
Slightly volatile
Operating Cash Flow Sales Ratio0.120.07540.1401
Slightly volatile
Days Of Inventory Outstanding143129173
Slightly volatile
Days Of Sales Outstanding13167.4888107
Slightly volatile
Cash Flow Coverage Ratios0.06550.0690.1692
Slightly volatile
Price To Book Ratio4.474.706211.2567
Slightly volatile
Fixed Asset Turnover3.423.34362.8446
Pretty Stable
Capital Expenditure Coverage Ratio2.462.5043.5245
Pretty Stable
Price Cash Flow Ratio26.020.27854.3293
Slightly volatile
Debt Ratio0.260.45970.3758
Slightly volatile
Cash Flow To Debt Ratio0.06550.0690.1692
Slightly volatile
Price Sales Ratio1.451.52846.5069
Slightly volatile
Asset Turnover0.630.42070.3889
Very volatile
Gross Profit Margin0.380.48740.4825
Slightly volatile
Price Fair Value4.474.706211.2567
Slightly volatile

Teva Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.9 B22.8 B24.8 B
Slightly volatile
Enterprise Value34.2 B32.5 B41.9 B
Slightly volatile

Teva Fundamental Market Drivers

Forward Price Earnings6.4392
Cash And Short Term Investments3.3 B

Teva Upcoming Events

31st of January 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Teva Pharma Financial Statements

Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue5.7 B3.1 B
Total Revenue16.5 B9.7 B
Cost Of Revenue8.5 B4.8 B
Sales General And Administrative To Revenue 0.07  0.05 
Research And Ddevelopement To Revenue 0.06  0.05 
Capex To Revenue 0.03  0.03 
Revenue Per Share 14.60  7.98 
Ebit Per Revenue(0.02)(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
How To Invest In Teva
Details
Is Teva Stock a good investment?
Details
What is Teva Pharma's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Teva Pharma Correlation against competitors.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(1.45)
Revenue Per Share
14.628
Quarterly Revenue Growth
(0.05)
Return On Assets
0.0509
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY